Abstract:Structural heterogeneity and the lack of in vivo real-time tracking of drug release are the utmost barriers for nanocarrier-mediated prodrugs in targeted therapy. Herein, we describe the strategy of molecularly precise self-assembly of monodisperse nanotheranostics for BPn-DCM-S-CPT (n = 0, 5 and 20) with fixed drug loadings (36%, 23% and 16%) and constant release capacities, permitting in vivo real-time targeted therapy. We focus on regulating the hydrophilic fragment length to construct stable, well-defined nanostructured assemblies. Taking the bis-condensed dicyanomethylene-4H-pyran (DCM) derivative as the activatable near-infrared (NIR) fluorophore, it makes full use of two terminal conjunctions: the hydrophobic disulfide-bridged anticancer prodrug camptothecin (CPT) and the hydrophilic oligomer-bridged biotin segment serving as an active targeting unit. From the rational design, only BP20-DCM-SCPT forms uniform and highly stable self-assemblies (ca. 80 nm, critical micelle concentration = 1.52 mu M) with several advantages, such as structural homogeneity, fixed drug loading efficiency, real-time drug release tracking and synergistic targeting (passive, active and activatable ability). More importantly, in vitro and in vivo experiments verify that the surface-grafted biotins of nanoassemblies are directly exposed to receptors on cancer cells, thus markedly facilitating cellular internalization. Notably, through synergistic targeting, BP20-DCM-S-CPT displays excellent tumor-specific drug release performance in HeLa tumor-bearing nude mice, which has significantly enhanced in vivo antitumor activity and nearly eradicates the tumor (IRT = 99.7%) with few side effects. For the first time, the specific molecularly precise self-assembly of BP20-DCM-S-CPT within a single-molecular framework has successfully achieved a single reproducible entity for real-time reporting of drug release and cancer therapeutic efficacy in living animals, providing a new insight into amphiphilic nanotheranostics for clinical translation.

A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy.

A Self-Immolative and DT-diaphorase-activatable Prodrug for Drug-Release Tracking and Therapy

A Sequential Enzyme-Activated and Light-Triggered Pro-Prodrug Nanosystem for Cancer Detection and Therapy.

A Theranostic Prodrug Based on FRET for Real-Time Drug Release Monitoring in Response to Biothiols.

A two-photon-activated prodrug for therapy and drug release monitoring

A Leucine Aminopeptidase-Activated Theranostic Prodrug for Cancer Diagnosis and Chemotherapy.

In Vivo and in Situ Tracking Cancer Chemotherapy by Highly Photostable NIR Fluorescent Theranostic Prodrug

Engineering Molecular Self-Assembly of Theranostic Nanoprobes for Dual-Modal Imaging-Guided Precise Chemotherapy

A gadolinium-complex-based theranostic prodrug for in vivo tumour-targeted magnetic resonance imaging and therapy

A Self-Immolative Prodrug Nanosystem Capable of Releasing A Drug and A Nir Reporter for in Vivo Imaging and Therapy

Molecularly Precise Self-Assembly of Theranostic Nanoprobes Within a Single-Molecular Framework for in Vivo Tracking of Tumor-Specific Chemotherapy.

Molecular imaging of telomerase and the enzyme activity-triggered drug release by using a conformation-switchable nanoprobe in cancerous cells

Nanomized Tumor-Microenvironment-active NIR Fluorescent Prodrug for Ensuring Synchronous Occurrences of Drug Release and Fluorescence Tracing

Dual-channel NIR Activatable Theranostic Prodrug for in Vivo Spatiotemporal Tracking Thiol-Triggered Chemotherapy.

A Telomerase‐Specific Doxorubicin‐Releasing Molecular Beacon for Cancer Theranostics

GSH-Activated NIR Fluorescent Prodrug for Podophyllotoxin Delivery.

Glutathione-responsive Prodrug Conjugates for Image-Guided Combination in Cancer Therapy

A polymeric prodrug for non-invasive, real-time reporting drug release based on “turn-on” fluorescent probes

Peptide-Driven Targeted Drug-Delivery System Comprising Turn-On Near-Infrared Fluorescent Xanthene-Cyanine Reporter for Real-Time Monitoring of Drug Release

An advanced multifunctional prodrug combining photodynamic therapy with chemotherapy for highly efficient and precise tumor ablation

Dimeric Drug Polymeric Micelles with Acid-Active Tumor Targeting and FRET-indicated Drug Release